Hospital
Seton Medical Center
Seton Medical Center was paid $4.94M by Medicaid between Jan 2018 and Sep 2021, across 220 billing codes. Its largest line is 0450, Emergency room services — 20% of everything it billed.
33Billing provider infoSETON MEDICAL CENTER
DALY CITY, CA 94015
DALY CITY, CA 94015
33aNPI1154428688assigned 09/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.94M
24GClaims268,889
24DCodes billed220
24AFirst – last monthJan 2018 – Sep 2021
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#226 of 410
Median peer was paid$6.90M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 107,032 | $1.92M | |
| 2019 | 103,024 | $1.80M | |
| 2020 | 55,572 | $1.15M | |
| 2021 | 3,261 | $78K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 20% | 16,417 | 14,944 | $986K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 4.5% | 3,724 | 3,719 | $220K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 3,342 | 3,015 | $180K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.4% | 8,749 | 6,679 | $169K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 1,468 | 1,279 | $162K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 1,083 | 1,039 | $161K |
| 80053 | Comprehensive metabolic panel | 3.1% | 16,666 | 15,619 | $155K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 1,316 | 1,245 | $137K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 19,622 | 17,763 | $123K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.5% | 2,203 | 1,934 | $123K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 2.0% | 1,563 | 1,536 | $99K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.8% | 5,756 | 5,700 | $90K |
208 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.8% | 7,313 | $87K |
| 0214 | 1.7% | 64 | $86K | |
| 0360 | 1.7% | 471 | $84K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 1,767 | $75K |
| 80061 | Lipid panel | 1.5% | 11,293 | $73K |
| 99283 | Emergency room visit (moderate) | 1.4% | 1,893 | $70K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 1,912 | $69K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 574 | $62K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 3,281 | $59K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 993 | $58K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 2,391 | $56K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 894 | $54K |
| 0121 | <1% | 27 | $46K | |
| 76830 | Ultrasound, transvaginal | <1% | 736 | $43K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 834 | $40K |
| 81001 | <1% | 12,242 | $38K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,501 | $38K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,144 | $37K |
| 74178 | <1% | 185 | $37K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 550 | $35K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 630 | $35K |
| 84484 | <1% | 3,471 | $32K | |
| 76770 | <1% | 698 | $31K | |
| 77065 | Tomosynthesis, mammo | <1% | 414 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 795 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,940 | $30K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 772 | $29K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 381 | $28K |
| 86480 | <1% | 711 | $28K | |
| 76642 | <1% | 492 | $27K | |
| J3490 | Unclassified drugs | <1% | 9,131 | $25K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,473 | $25K |
| 76536 | <1% | 479 | $24K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 183 | $24K |
| 83690 | <1% | 2,673 | $23K | |
| Z7502 | <1% | 612 | $22K | |
| 71250 | <1% | 250 | $22K | |
| 77080 | <1% | 1,533 | $19K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,663 | $19K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 207 | $18K |
| 81025 | <1% | 2,253 | $18K | |
| 84153 | <1% | 1,205 | $17K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 310 | $17K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,916 | $17K |
| 83880 | <1% | 1,537 | $17K | |
| 0111 | <1% | 19 | $16K | |
| 72110 | <1% | 392 | $16K | |
| 93017 | <1% | 331 | $16K | |
| 73564 | <1% | 567 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,994 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 245 | $15K |
| 82043 | <1% | 5,418 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 271 | $15K |
| 77066 | Tomosynthesis, mammo | <1% | 134 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 739 | $14K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 666 | $13K |
| 99070 | <1% | 5,006 | $12K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 164 | $12K |
| 73030 | <1% | 473 | $12K | |
| 82550 | <1% | 3,775 | $11K | |
| 84439 | <1% | 2,088 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,825 | $11K |
| 73630 | <1% | 455 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 669 | $11K |
| 73610 | <1% | 416 | $11K | |
| 77412 | <1% | 158 | $10K | |
| 0710 | <1% | 236 | $9K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 14 | $9K |
| 87040 | <1% | 655 | $9K | |
| 87186 | <1% | 1,242 | $9K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 276 | $8K |
| 82274 | <1% | 1,627 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 24 | $8K |
| 83605 | <1% | 729 | $8K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 366 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,604 | $7K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 313 | $7K |
| 93350 | <1% | 108 | $7K | |
| 84466 | <1% | 1,382 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 42 | $7K |
| 85610 | <1% | 2,312 | $7K | |
| 86803 | <1% | 419 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 148 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 763 | $6K |
| 87077 | <1% | 1,415 | $6K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 159 | $6K |
| 83970 | <1% | 353 | $5K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 1,044 | $5K |
| 93971 | <1% | 57 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $5K |
| 80069 | <1% | 1,212 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 39 | $4K |
| 82962 | <1% | 1,153 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 234 | $4K |
| 85730 | <1% | 765 | $4K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 417 | $4K |
| 84550 | <1% | 1,960 | $4K | |
| 82728 | <1% | 813 | $4K | |
| 83735 | <1% | 881 | $4K | |
| 83540 | <1% | 1,411 | $4K | |
| 80076 | <1% | 764 | $3K | |
| 73110 | <1% | 143 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $3K |
| 73130 | <1% | 120 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 511 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 531 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 141 | $3K |
| 84481 | <1% | 372 | $3K | |
| 87340 | <1% | 289 | $3K | |
| 85379 | <1% | 238 | $3K | |
| 82607 | <1% | 1,543 | $3K | |
| 82746 | <1% | 453 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 503 | $2K |
| 72100 | <1% | 88 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 816 | $2K |
| 85027 | <1% | 679 | $2K | |
| 82553 | <1% | 197 | $2K | |
| 84460 | <1% | 1,508 | $2K | |
| 94060 | <1% | 68 | $2K | |
| 94010 | <1% | 328 | $2K | |
| 94644 | <1% | 75 | $2K | |
| 86706 | <1% | 166 | $2K | |
| 72050 | <1% | 39 | $2K | |
| 86780 | <1% | 202 | $2K | |
| 82040 | <1% | 679 | $2K | |
| 0250 | <1% | 285 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 29 | $1K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 366 | $1K |
| 84450 | <1% | 680 | $1K | |
| 85652 | <1% | 1,010 | $1K | |
| 84100 | <1% | 538 | $1K | |
| 0510 | <1% | 31 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 231 | $1K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 50 | $1K |
| 82378 | <1% | 85 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,186 | $993.44 |
| 81005 | <1% | 291 | $816.44 | |
| 99199 | Unlisted special service, procedure or report | <1% | 16 | $778.23 |
| 82150 | <1% | 114 | $744.54 | |
| 74018 | <1% | 44 | $722.59 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 135 | $691.77 |
| 86038 | <1% | 230 | $680.14 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 32 | $635.71 |
| 87070 | <1% | 68 | $627.42 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 109 | $543.86 |
| 86901 | <1% | 99 | $479.64 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 63 | $463.56 |
| 85611 | <1% | 61 | $393.03 | |
| 72114 | <1% | 12 | $387.82 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 16 | $381.30 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 85 | $332.81 |
| Z7610 | <1% | 41 | $326.64 | |
| 86900 | <1% | 100 | $317.96 | |
| 83520 | <1% | 55 | $312.08 | |
| 94729 | <1% | 14 | $305.88 | |
| 94726 | <1% | 14 | $280.38 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 29 | $267.33 |
| 73565 | <1% | 12 | $264.07 | |
| 72070 | <1% | 12 | $262.14 | |
| 82565 | <1% | 114 | $262.08 | |
| 82248 | <1% | 108 | $244.90 | |
| 84156 | <1% | 285 | $204.97 | |
| 73080 | <1% | 12 | $202.18 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 43 | $195.69 |
| 80074 | <1% | 12 | $177.66 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 46 | $162.01 |
| 85007 | <1% | 76 | $150.08 | |
| J2704 | Injection, propofol, 10 mg | <1% | 17 | $123.19 |
| 83883 | <1% | 14 | $122.80 | |
| 82947 | <1% | 30 | $117.39 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 12 | $106.44 |
| 84075 | <1% | 75 | $87.02 | |
| 82105 | <1% | 27 | $67.88 | |
| 86140 | <1% | 33 | $60.40 | |
| 84132 | <1% | 32 | $60.16 | |
| 82272 | <1% | 84 | $51.02 | |
| 82533 | <1% | 14 | $30.91 | |
| 86334 | <1% | 12 | $29.25 | |
| 86800 | <1% | 27 | $28.54 | |
| 0272 | <1% | 108 | $22.14 | |
| 86431 | <1% | 13 | $17.85 | |
| 83516 | <1% | 16 | $17.20 | |
| 82985 | <1% | 80 | $16.41 | |
| 86376 | <1% | 13 | $13.16 | |
| 85045 | 0% | 13 | $0.00 | |
| 0300 | 0% | 168 | $0.00 | |
| 0320 | 0% | 149 | $0.00 | |
| 0424 | 0% | 44 | $0.00 | |
| 82088 | 0% | 13 | $0.00 | |
| 0730 | 0% | 93 | $0.00 | |
| 0412 | 0% | 26 | $0.00 | |
| 0302 | 0% | 15 | $0.00 | |
| 0483 | 0% | 24 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 1,350 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 459 | $0.00 |
| 0301 | 0% | 169 | $0.00 | |
| 0258 | 0% | 155 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 126 | $0.00 |
| 0271 | 0% | 44 | $0.00 | |
| 0305 | 0% | 139 | $0.00 | |
| 0352 | 0% | 14 | $0.00 | |
| 0420 | 0% | 42 | $0.00 | |
| 0306 | 0% | 129 | $0.00 | |
| 84244 | 0% | 13 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 30 | $0.00 |
| 0255 | 0% | 14 | $0.00 | |
| 0307 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFERRELLI, JOHN (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Seton Medical Center | Daly City, CA | $411.87 |
| Seton Medical Center | Daly City, CA | $7.08 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.